Skip to content

Sterotactic radiotherapy and chemotherapy to improve surgical resection and reduce recurrence

Neoadjuvant treatment versus upfront surgery in Resectable pancreatic cancer (NEVUS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/09/021082
Enrollment
80
Registered
2019-09-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified

Interventions

Intervention1: Arm B experimental Arm SBRT followed by 2 cycles of folfirinox: Patients in the experimental arm after SBRT will received 2 cycles of modified folfirino post 1 to 2 weeks of SBRT fluo

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Radiologically defined to be resectable as per the NCCN guidelines Version 2 on a Triphasic CECT scan amenable to oncological surgical resection. Selected ampullary adenocarcinomas involving pancreatic head or abutting or involving vessels will be included. -Patients with no evidence of regional or distant metastatic disease based on CT scan of the chest/ abdomen/pelvis -No significant co-morbidities that would interfere with treatment and fit for general anaestheia -Reliable for follow-up and signed informed consent. -Karnofsky performance status (KPS) between 70 and 100. -Patients with tumors primarily of the body or tail of the pancreas requiring a distal pancreaticoduodenectomy.

Exclusion criteria

Exclusion criteria: -Prior surgical resection of any pancreatic malignancy -Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields -History of prior allergic reactions attributed to compounds of CT or MRI contrast -Any prior therapy for pancreatic cancer

Design outcomes

Primary

MeasureTime frame
Incidence of margin negative resection, defined as the absence of viable tumor cells more than 1 mm from the inked surgical marginTimepoint: 48 months

Secondary

MeasureTime frame
-Median overall survival -Pathological response -Incidence of 30 day post operative complications -Radiological response per Response Evaluation by RECIST Loco-regional recurrence free survival, defined with follow-up radiological assessment.- Loco-regional recurrence free survival Timepoint: 48 months

Countries

India

Contacts

Public ContactAkanksha Anup

Tata Memorial Hospital

akkuanup27@gmail.com9890236460

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026